This research study is about worldwide drug discovery R&D. The report discusses the current status of new drug products that are in the clinical trials pipeline and analyzes the data from several points of view. The comprehensive report provides readers with data gathered in a mid-2004 survey to identify, count, measure and analyze key developments driving R&D in the drug industry.

The worldwide drug making industry is both complex and challenging for all business participants. The study reviews key areas of the top 55 global pharma and biotech companyÕs drug R&D activities and highlights their strategies and individual drug R&D clinical pipelines.

This must-have report takes the point of view of major disease categories and discusses key health issues identified through worldwide disease demographic data. The study divides ten major disease categories identifies 259 disease indications that drug makers are addressing with new drugs.

This research report analyzes the major disease categories of the drugs in 873 clinical trials that the drug companies are developing and ranks the most promising areas likely to yield high potential drug products. The report identifies potential blockbusters and maps them by potential market value and likely launch year through 2009.

The report discusses these important items with interesting and useful findings. This study uses more than 53 tables and charts to illustrate the findings. Detailed information about the activities of the top companies important to this market is listed in numerous areas of this report.

1. Current Status
  1.1 Rx Drug Discovery R&D Steps and Timelines
  1.2 Review of Rx R&D Progress
    1.2.1 Drug R&D Productivity Trends
    1.2.2 Annual Pharma Industry R&D Budgets
    1.2.3 Annual Regulatory Approval Trends
  1.3 Disease Demographics in the Developed World
    1.3.1 Pharma Companies Use Disease Demographics in R&D Planning
    1.3.2 Monitoring and Analyzing Population Health Data
    1.3.3 Major Disease Categories and Pharma Business Opportunities

2. Cancer, Gastrointestinal and Metablolic Disease Drug R&D
    Development Strategy by Company
  2.1 Cancer Drug R&D Development Activity and Strategy
  2.2 Cancer R&D Programs by Major Companies
        Total 31 Companies
        Common Research Item
          ·R&D Structure (R&D Budget, # of Researchers, Strategic Alliance)
          ·Researcher Comment
          ·R&D Drug Pipeline: Clinical Trials by Therapy
                     (Product Name, Generic Name, Indication, Phase, Target Year, Market Size ($)
  2.3 Gastrointestinal Disease Drug R&D Development Activity and Strategy
  2.4 Gastrointestinal Disease R&D Programs by Major Company
    Total 13 Companies
    Common Research Item
          ·R&D Structure (R&D Budget, # of Researchers, Strategic Alliance)
          ·Researcher Comment
          ·R&D Drug Pipeline: Clinical Trials by Therapy
                    (Product Name, Generic Name, Indication, Phase, Target Year, Market Size ($)
  2.5 Metabolic Disease Drug R&D Development Activity and Strategy
  2.6 Metabolic Disease R&D Programs by Major Company
    Total 12 Companies
    Common Research Item
          ·R&D Structure (R&D Budget, # of Researchers, Strategic Alliance)
          ·Researcher Comment
          ·R&D Drug Pipeline: Clinical Trials by Therapy
                     (Product Name, Generic Name, Indication, Phase, Target Year, Market Size ($)
3. CNS, Infectious Disease, Respiratory and Urogenital Disease Drug
    R&D Development Strategy by Company
  3.1 CNS Drug R&D Development Activity and Strategy
  3.2 CNS Drug R&D by Major Company
      Total 24 Companies
      Common Research Item
          ·R&D Structure (R&D Budget, # of Researchers, Strategic Alliance)
          ·Researcher Comment
          ·R&D Drug Pipeline: Clinical Trials by Therapy
                    (Product Name, Generic Name, Indication, Phase, Target Year, Market Size ($)
    3.3 Infectious Disease Drug R&D Development Activity and Strategy
    3.4 Infectious Disease Drug R&D by Major Company
    Total 22 Companies
    Common Research Item
          ·R&D Structure (R&D Budget, # of Researchers, Strategic Alliance)
          ·Researcher Comment
          ·R&D Drug Pipeline: Clinical Trials by Therapy
                    (Product Name, Generic Name, Indication, Phase, Target Year, Market Size ($)
  3.5 Respiratory Drug R&D Development Activity and Strategy
  3.6 Respiratory Drug R&D by Major Company
      Total 11Companies
      Common Research Item
          ·R&D Structure (R&D Budget, # of Researchers, Strategic Alliance)
          ·Researcher Comment
          ·R&D Drug Pipeline: Clinical Trials by Therapy
                    (Product Name, Generic Name, Indication, Phase, Target Year, Market Size ($)
  3.7 Urogenital Drug R&D Development Activity and Strategy
  3.8 Urogenital Drug R&D by Major Company
    Total 11 Companies
    Common Research Item
          ·R&D Structure (R&D Budget, # of Researchers, Strategic Alliance)
          ·Researcher Comment
          ·R&D Drug Pipeline: Clinical Trials by Therapy
                     (Product Name, Generic Name, Indication, Phase, Target Year, Market Size ($)

4. Cardiovascular, Musculoskeletal and Other Disease Drug R&D Development Strategy by Company
  4.1 Cardiovascular Disease Drug R&D Development Activity and Strategy
  4.2 Cardiovascular Disease Drug R&D by Major Company
      Total 21 Companies
      Common Research Item
          ·R&D Structure (R&D Budget, # of Researchers, Strategic Alliance)
          ·Researcher Comment
          ·R&D Drug Pipeline: Clinical Trials by Therapy
                    (Product Name, Generic Name, Indication, Phase, Target Year, Market Size ($)
  4.3 Musculoskeletal Disease Drug R&D Development Activity and Strategy
  4.4 Musculoskeletal Disease Drug R&D by Major Company
    Total 11 Companies
    Common Research Item
          ·R&D Structure (R&D Budget, # of Researchers, Strategic Alliance)
          ·Researcher Comment
          ·R&D Drug Pipeline: Clinical Trials by Therapy
                    (Product Name, Generic Name, Indication, Phase, Target Year, Market Size ($)
  4.5 'Other Disease' Drug R&D Development Activity and Strategy
  4.6 'Other Disease' Drug R&D by Major Company
      Total 14 Companies
      Common Research Item
          ·R&D Structure (R&D Budget, # of Researchers, Strategic Alliance)
          ·Researcher Comment
          ·R&D Drug Pipeline: Clinical Trials by Therapy
                     (Product Name, Generic Name, Indication, Phase, Target Year, Market Size ($)

5. Analysis of Top Rx Drug R&D Vendors vs. Competitors
  5.1 Cancer Indications: Analysis of Drug R&D Competitors By Value Factor
  5.2 Cardiovascular Indications: Analysis of Drug R&D Competitors By Value Factor
  5.3 CNS Indications: Analysis of Drug R&D Competitors By Value Factor
  5.4 Gastrointestinal Indications: Analysis of Drug R&D Competitors By Value Factor
  5.5 Infectious Disease Indications: Analysis of Drug R&D Competitors By Value Factor
  5.6 Metabolic Indications: Analysis of Drug R&D Competitors By Value Factor
  5.7 Musculoskeletal Indications: Analysis of Drug R&D Competitors By Value Factor
  5.8 Respiratory Indications: Analysis of Drug R&D Competitors By Value Factor
  5.9 Urogenital Indications: Analysis of Drug R&D Competitors By Value Factor
  5.10 'Other' Indications: Analysis of Drug R&D Competitors By Value Factor
  5.11 Summary of Analysis
  5.11.1Main Findings
  5.11.2Leading Five Therapy Areas
  5.11.3Competition: Big Rx Companies vs. Small Rx Companies

6. Identifying Potential Blockbusters
  6.1 Top Therapy Areas
  6.2 Top Potential Blockbusters

7. Conclusions and Other Thoughts
  7.1 Drug R&D Progress and Trends
  7.2 Disease Demographics Can Shape Pharma Markets
  7.3 Drug R&D by Therapy Areas and Competition
  7.4 Finding Potential Blockbuster Drugs
  7.5 Other Thoughts

8. Appendix 1 - Links to Small Pharmaceutical Companies Mentioned in Data Tables
9. Appendix 2 - Links to Worldwide Human Drug Regulatory Organizations

List of Tables
Table 1. Pharma R&D Productivity by Approved NMEs, 1994-2004E
Table 2. Pharma Industry R&D Spending vs. US NIH FY Budgets, 1994-2004E
Table 3. Median FDA Approval Timelines and Approved NMEs 1994-2004
Table 4. Summary of Patient Populations Sorted by Total Existing Patients
Table 5. Estimated Patient Populations by Disease in the Developed World
Table 6. Top 5 Health Risk Factors Leading to Death
Table 7. Cancer Drug Pipelines by Indication
Table 8. Gastrointestinal Disease Drug Pipelines by Indication
Table 9. Metabolic Disease Drug Pipelines by Indication
Table 10. CNS Drug Pipelines by Indication
Table 11. Infectious Disease Drug Pipelines by Indication
Table 12. Respiratory Drug Pipelines by Indication
Table 13. Urogenital Drug Pipelines by Indication
Table 14. Cardiovascular Drug Pipelines by Indication
Table 15. Musculoskeletal Drug Pipelines by Indication
Table 16. 'Other Disease' Drug Pipelines by Indication
Table 17. Top Cancer Indications Sorted By Value Factor
Table 18. Cancer Indications, Top Companies & Rx's in R&D By Value Factor
Table 19. Top Cardiovascular Indications By Value Factor
Table 20. Cardiovascular Indications, Top Companies & Rx's in R&D By Value Factor
Table 21. Top CNS Indications By Value Factor
Table 22. CNS Indications, Top Companies & Rx's in R&D By Value Factor
Table 23. Top Gastrointestinal Indications By Value Factor
Table 24. Gastrointestinal Indications, Top Companies & Rx's in R&D By Value Factor
Table 25. Top Infection Indications By Value Factor
Table 26. Infectious Disease Indications, Top Companies & Rx's in R&D By Value Factor
Table 27. Top Metabolic Indications By Value Factor
Table 28. Metabolic Disease Indications, Top Companies & Rx's in R&D By Value Factor
Table 29. Top Musculoskeletal Indications By Value Factor
Table 30. Musculoskeletal Indications, Top Companies & Rx's in R&D By Value Factor
Table 31. Top Respiratory Indications By Value Factor
Table 32. Respiratory Indications, Top Companies & Rx's in R&D By Value Factor
Table 33. Top Urogenital Indications By Value Factor
Table 34. Urogenital Indications, Top Companies & Rx's in R&D By Value Factor
Table 35. Top 'Other' Indications By Value Factor
Table 36. 'Other' Indications, Top Companies & Rx's in R&D By Value Factor
Table 37. Summary of Analysis by Major Therapy Area and Value Factor
Table 38. Major Therapy Areas by Number of Blockbuster Drugs
Table 39. Estimated Revenues of Potential Blockbusters by Year of Release
Table 40. Cancer Drugs, Peak Market Potential and Est. Launch Year
Table 41. Cardiovascular Drugs, Peak Market Potential and Est. Launch Year
Table 42. CNS Drugs, Peak Market Potential and Est. Launch Year
Table 43. Gastrointestinal Drugs, Peak Market Potential and Est. Launch Year
Table 44. Infectious Disease Drugs, Peak Market Potential and Est. Launch Year
Table 45. Metabolic Drugs, Peak Market Potential and Est. Launch Year
Table 46. Musculoskeletal Drugs, Peak Market Potential and Est. Launch Year
Table 47. Respiratory Drugs, Peak Market Potential and Est. Launch Year
Table 48. Urogenital Drugs, Peak Market Potential and Est. Launch Year
Table 49. 'Other' Drugs, Peak Market Potential and Est. Launch Year

List of Illustrations
Figure 1. Drug R&D and Approval Process for New Rx Products
Figure 2. Pharma R&D Productivity by Approved
                NMEs, 1994-2004E
Figure 3. Pharma Industry R&D Spending vs. US NIH FY
                Budgets, 1994-2004E
Figure 4. Median FDA Approval Timelines and Approved
                NMEs 1994-2004

FOR ORDER OR INQUIRY, PLEASE CLICK "ORDER / INQUIRY FORM"